Unmasking the complexities of mucinous ovarian carcinoma
- PMID: 20332054
- PMCID: PMC4265465
- DOI: 10.1016/j.ygyno.2010.02.010
Unmasking the complexities of mucinous ovarian carcinoma
Abstract
Objective: Most collaborative studies for the treatment of primary and recurrent ovarian cancer have grouped all epithelial ovarian cancers together, leading to a common therapeutic approach to all the different subtypes. Emerging data, however, support the hypothesis that primary mucinous ovarian cancers are unique histologically, molecularly, and clinically from other epithelial subtypes. The objective of our review was to identify and synthesize the most current information on mucinous ovarian carcinoma with regard to pathologic, molecular, and clinical distinctions.
Methods: We searched PubMed for English-language articles with the MeSH term "mucinous ovarian carcinoma" published between 1990 and 2009.
Results: On pathologic examination, primary invasive mucinous ovarian cancer often can be seen next to areas of benign and borderline mucinous histology, suggesting a continuum to malignant progression not observed in the other epithelial ovarian lesions. When compared to serous ovarian tumors, primary mucinous ovarian tumors have a significantly higher prevalence of KRAS mutations and a lower frequency of BRCA and p53 abnormalities. In addition, metastatic primary disease and recurrent mucinous cancers have a substantially worse prognosis than other epithelial ovarian cancers and are largely platinum and taxane resistant.
Conclusions: Primary mucinous ovarian cancer should be considered separate from the other epithelial ovarian cancers. Ongoing clinical trials in this disease will likely offer improvements in chemotherapeutic agents used to treat women with primary and recurrent mucinous ovarian cancer.
Copyright 2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4265465/bin/nihms645343f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4265465/bin/nihms645343f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4265465/bin/nihms645343f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4265465/bin/nihms645343f4.gif)
Similar articles
-
Mucinous tumors of the ovary: current thoughts on diagnosis and management.Curr Oncol Rep. 2014 Jun;16(6):389. doi: 10.1007/s11912-014-0389-x. Curr Oncol Rep. 2014. PMID: 24777667 Free PMC article. Review.
-
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.Gynecol Oncol. 2003 Aug;90(2):378-81. doi: 10.1016/s0090-8258(03)00264-6. Gynecol Oncol. 2003. PMID: 12893203
-
TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18. Exp Mol Pathol. 2013. PMID: 23965232
-
Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8. BMC Cancer. 2015. PMID: 25986173 Free PMC article.
-
Mucinous epithelial ovarian carcinoma.Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57. doi: 10.1093/annonc/mdw087. Ann Oncol. 2016. PMID: 27141073 Review.
Cited by
-
Factors Affecting the Diagnostic Discordance Between Frozen and Permanent Sections in Mucinous Ovarian Tumors.Int J Womens Health. 2024 May 17;16:853-863. doi: 10.2147/IJWH.S458138. eCollection 2024. Int J Womens Health. 2024. PMID: 38774151 Free PMC article.
-
Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.Diagn Pathol. 2023 Apr 20;18(1):49. doi: 10.1186/s13000-023-01340-w. Diagn Pathol. 2023. PMID: 37081552 Free PMC article.
-
Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.Front Oncol. 2023 Feb 2;12:1112152. doi: 10.3389/fonc.2022.1112152. eCollection 2022. Front Oncol. 2023. PMID: 36818673 Free PMC article.
-
Giant ovarian mucinous cystadenocarcinoma: A case report.Clin Case Rep. 2022 Jul 14;10(7):e6067. doi: 10.1002/ccr3.6067. eCollection 2022 Jul. Clin Case Rep. 2022. PMID: 35846900 Free PMC article.
-
Prognosis in primary mucinous ovarian carcinoma: focusing on the five pathological findings indicating metastatic mucinous carcinoma to the ovary.J Gynecol Oncol. 2022 Mar;33(2):e18. doi: 10.3802/jgo.2022.33.e18. Epub 2021 Dec 6. J Gynecol Oncol. 2022. PMID: 34910399 Free PMC article.
References
-
- Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 2004;23:200–5. - PubMed
-
- Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, Shepherd JH, Ind T, Bridges J, Harrington K, Kaye SB, Gore ME. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040–4. - PubMed
-
- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6. - PubMed
-
- Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708. - PubMed
-
- Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106–15. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous